B
Bull
Bull · 25%ERNA
$2.61
Scenario price
$4.570
-0.159 (-3.48%)At close
Loading chart…
- High
- 4.990
- Open
- 4.760
- VWAP
- 4.71
- Vol
- 26.72K
- Mkt Cap
- 9.47M
- Low
- 4.560
- Amount
- 125.76K
- EV/EBITDA, TTM
- 0.00
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
AI analysis of Ernexa Therapeutics Inc (ERNA)
buyEterna Therapeutics Inc (ERNA) presents a compelling buy opportunity at its current price of $4.57. The stock has a favorable analyst price target of $30, indicating significant upside potential of approximately 557%. Additionally, the recent positive news regarding the validation of its anti-tumor therapy and a narrowing net loss of $5.51 million in Q1 2026, down from $8.20 million the previous year, suggests improving financial health. However, the main risk is its current year-to-date change of -84.24%, indicating high volatility and potential investor caution.
Valuation Metrics
The current forward P/E ratio for Ernexa Therapeutics Inc (ERNA) is 0.00, compared to its 5-year average forward P/E of -2.06.
Alphio AI Price Scenarios for ERNA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
5.008-10NewsfilterErnexa Appoints New Director to Strengthen Leadership Team
8.507-24GlobenewswireErnexa's Innovative Approach to Cancer Treatment
- 8.507-24Newsfilter
Ernexa's Innovative Approach to Cancer Treatment
- 8.507-15Newsfilter
NeOnc, Ernexa, and VivoSim Announce Key Developments
9.007-15Yahoo FinanceErnexa Therapeutics Releases New Anti-Tumor Data
ERNA FAQ — answered by Alphio AI
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Eterna Therapeutics Inc (ERNA) presents a compelling buy opportunity at its current price of $4.57. The stock has a favorable analyst price target of $30, indicating significant upside potential of approximately 557%. Additionally, the recent positive news regarding the validation of its anti-tumor therapy and a narrowing net loss of $5.51 million in Q1 2026, down from $8.20 million the previous year, suggests improving financial health. However, the main risk is its current year-to-date change of -84.24%, indicating high volatility and potential investor caution.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.